AZN
NEUTRALAstraZeneca CFO Sells Shares
The CFO of the pharmaceutical company has sold a portion of their American Depositary Shares.
AstraZeneca
13,532.00GBX
0.28%
Market Cap
209.78B
Volume
1.32M
64% of avg
P/E Ratio
1874.24
EPS (TTM)
7.22
Beta
0.17
Day Range
13,408.00p - 13,574.00p
52 Week Range
9,573.50p13,532.00p13,574.00p
13,532.00p
Upcoming Events
AZN
NEUTRALAstraZeneca Announces Director Share Transfer
The biopharmaceutical company announces its CEO has gifted shares to family members.
AZN
VERY GOODAstraZeneca Delivers Strong 9M 2025 Results, Beats Expectations
The biopharmaceutical company reported strong 9M 2025 results, with total revenue up 10% and core EPS up 15% compared to the prior year period, beating market expectations.
AZN
NEUTRALAstraZeneca Announces Director Appointment
The healthcare company has announced the appointment of a new non-executive director to its board.
AZN
NEUTRALAstraZeneca's Koselugo approved in EU for rare genetic condition
The biopharmaceutical company has received EU approval for its Koselugo treatment for a rare genetic condition affecting the nerves.
AZN
NEUTRALAstraZeneca Receives EU Approval for Tezspire to Treat Chronic Rhinosinusitis with Nasal Polyps
The biopharmaceutical company has received European Commission approval for its Tezspire treatment for chronic rhinosinusitis with nasal polyps.
AZN
NEUTRALAstraZeneca's Tezspire Approved by FDA for Chronic Rhinosinusitis with Nasal Polyps
The biopharmaceutical company has received FDA approval for its Tezspire treatment for a chronic respiratory condition.
AZN
NEUTRALAstraZeneca's Saphnelo Subcutaneous Formulation Recommended for EU Approval
The biopharmaceutical company received a positive CHMP opinion for a subcutaneous version of its lupus drug Saphnelo, which could provide patients with a more convenient administration option.
AZN
GOODAstraZeneca Strikes Historic Deal with US Govt to Lower Medicine Prices
The biopharmaceutical company has reached a historic agreement with the US government to lower the cost of medicines for American patients, while preserving the country's role as a global leader in innovation.
AZN
NEUTRALAstraZeneca's Baxdrostat meets primary endpoint in Phase III trial for resistant hypertension
The biopharmaceutical company reports that its drug baxdrostat demonstrated a statistically significant and clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure compared to placebo in a Phase III trial for resistant hypertension.